<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296396</url>
  </required_header>
  <id_info>
    <org_study_id>HD036801-PACT</org_study_id>
    <nct_id>NCT04296396</nct_id>
  </id_info>
  <brief_title>Opioid Prescription After Cesarean Trial</brief_title>
  <acronym>PACT</acronym>
  <official_title>Prescription After Cesarean Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-inferiority randomized trial of 5,500 women with a cesarean delivery randomized prior to&#xD;
      discharge to either an individualized opioid prescription protocol (IOPP) that includes&#xD;
      shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority multi-center unblinded randomized trial of 5,500 women undergoing a&#xD;
      cesarean delivery who are randomized before discharge to either an individualized opioid&#xD;
      prescription protocol (IOPP) that includes shared decision making or to a fixed opioid&#xD;
      prescription of 20 tablets of oxycodone 5mg. The primary endpoint is the presence/absence of&#xD;
      moderate to severe pain at 1 week after discharge. Moderate to severe pain is defined as a&#xD;
      value of 4 or higher on the Brief Pain Inventory worst pain scale (0 to 10) in the last 24&#xD;
      hours. Consenting women will be assigned in a 1:1 ratio to one of the two arms using a secure&#xD;
      internet based randomization system maintained centrally by the Data Coordinating Center&#xD;
      (DCC). Randomization will be stratified by site. Women will be followed through 90 days&#xD;
      postpartum.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to either an individualized opioid prescription protocol (IOPP) that includes shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate to Severe Worst Pain Score at 1 week post discharge</measure>
    <time_frame>1 week post hospital discharge</time_frame>
    <description>Proportion of participants with moderate to severe pain at 1 week post-discharge; moderate to severe pain is defined as a value of 4 or higher on the Brief Pain Inventory worst pain in the last 24 hours numeric scale (from 0 to 10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid prescription filled beyond that prescribed at discharge</measure>
    <time_frame>2 weeks post discharge, 6 weeks postpartum, and 90 days postpartum</time_frame>
    <description>Proportion of participants with opioid prescription filled (beyond that prescribed at discharge) between one week post discharge and 1) two weeks post-discharge, 2) six weeks postpartum, and 3) ninety days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opioid prescriptions filled</measure>
    <time_frame>1week post discharge, 2 weeks post discharge, 6 weeks postpartum, 90 days postpartum</time_frame>
    <description>Total number of opioid prescriptions filled by one and two weeks post-discharge, and six weeks and ninety days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of opioid tablets prescribed and unused</measure>
    <time_frame>1 week post discharge, 2 weeks post discharge, 6 weeks postpartum, 90 days postpartum</time_frame>
    <description>Number of opioid tablets prescribed and unused from discharge to 1 week and 2 weeks post discharge, and 6 weeks and 90 days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of morphine milligram equivalents used</measure>
    <time_frame>1 week post discharge, 2 weeks post discharge, 6 weeks postpartum, 90 days postpartum</time_frame>
    <description>Total morphine milligram equivalents (MME) used from discharge to 1 week and 2 weeks post-discharge, and 6 weeks and 90 days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain severity scores (worst, least, average, current)</measure>
    <time_frame>2 weeks post discharge and 6 weeks postpartum and 90 days postpartum</time_frame>
    <description>Pain severity scores (worst, least, average, current) in last 24 hours assessed on the Brief Pain Inventory numeric scale from 0 to 10 at 2 weeks post-discharge, and 6 weeks and 90 days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference scores</measure>
    <time_frame>1 week post discharge, 2 weeks post discharge, 6 weeks postpartum, 90 days postpartum</time_frame>
    <description>Pain interference scores in the last week assessed on the Brief Pain Inventory (numeric scale from 0 to 10) at 1 and 2 weeks post-discharge, and 6 weeks and 90 days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of change in overall pain</measure>
    <time_frame>1 week post discharge, 2 weeks post discharge, 6 weeks postpartum, 90 days postpartum</time_frame>
    <description>Proportion of participants with global impression of change in overall pain (improved, no change, worse) at 1 and 2 weeks post-discharge, and 6 weeks and 90 days postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant hospital readmissions</measure>
    <time_frame>6 weeks postpartum</time_frame>
    <description>Proportion of infants readmitted to the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal postpartum weight retention</measure>
    <time_frame>6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal depression score â‰¥ 13</measure>
    <time_frame>6 weeks postpartum</time_frame>
    <description>The proportion of participants with a score of 13 or higher on the Edinburgh Postnatal Depression Scale. The minimum score is 0 and the maximum score is 30. Higher scores indicate worse outcomes, where persons scoring about 13 are likely to be suffering from a depressive illness. The scale indicates how the respondent has felt during the previous week.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5500</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Opioid Use</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Individualized Opioid Prescription</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized opioid prescription protocol and shared decision making</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Opioid Prescription</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>fixed opioid prescription of 20 tablets of oxycodone 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0 to 20 tablets of oxycodone 5mg</intervention_name>
    <description>Individualized opioid prescription protocol (IOPP) that includes shared decision making</description>
    <arm_group_label>Individualized Opioid Prescription</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed opioid prescription</intervention_name>
    <description>20 tablets of oxycodone 5mg</description>
    <arm_group_label>Fixed Opioid Prescription</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post cesarean delivery (combined vaginal/cesarean deliveries are not eligible)&#xD;
&#xD;
          -  Singleton, twin or triplet gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An opioid prescription filled during the current pregnancy&#xD;
&#xD;
          -  Known history of opioid use disorder, by medical record review&#xD;
&#xD;
          -  Contraindication to opioids (oxycodone)&#xD;
&#xD;
          -  Contraindications to both acetaminophen and ibuprofen&#xD;
&#xD;
          -  Significant surgical procedures (e.g., hysterectomy) prior to randomization as pain&#xD;
             trajectory will be completely different&#xD;
&#xD;
          -  Fetal or neonatal death prior to randomization&#xD;
&#xD;
          -  Inability to randomize within 1 day before planned discharge from the hospital&#xD;
&#xD;
          -  Inability to participate in shared decision making as assessed by research staff&#xD;
&#xD;
          -  Language barrier (non-English or Spanish speaking)&#xD;
&#xD;
          -  Participation in this trial in a previous pregnancy&#xD;
&#xD;
          -  Participation in another intervention study that influences the primary outcome in&#xD;
             this trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Bremer, MD, PhD, MAS</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Clifton, Ph.D.</last_name>
    <phone>301-881-9260</phone>
    <email>rclifton@bsc.gwu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cora MacPherson, Ph.D.</last_name>
    <phone>301-881-9260</phone>
    <email>coram@bsc.gwu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janatha Grant, RN</last_name>
      <phone>205-996-6268</phone>
      <email>jsgrant@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan TN Tita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Mallett, RN</last_name>
      <phone>312-503-3200</phone>
      <email>g-mallett@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Miller, Md, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bousleiman, RN</last_name>
      <phone>212-305-4348</phone>
      <email>sb1080@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Wapner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>17599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Clark, RN BSN</last_name>
      <phone>919-350-6117</phone>
      <email>kelly_clark@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John M. Thorp Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve-Metrohealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Dalton, RN</last_name>
      <phone>216-778-7533</phone>
      <email>wdalton@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Bailit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bartholomew, RN,BSN,CCRP</last_name>
      <phone>614-685-3229</phone>
      <email>Anna.Bartholomew@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Maged Costantine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Fazio, RN</last_name>
      <phone>267-273-8574</phone>
      <email>christina.fazio@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Parry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Boyce, RN</last_name>
      <phone>412-527-8118</phone>
      <email>tessje@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hyagriv Simhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown Univeristy</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Allard, RN</last_name>
      <phone>401-274-1122</phone>
      <email>dallard@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Dwight J Rouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar, MSN</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>George R Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felecia Ortiz, RN</last_name>
      <phone>713-500-6467</phone>
      <email>felecia.ortiz@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Suneet Chauhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Sowles, RN, BSN, CCRP</last_name>
      <phone>801-585-5499</phone>
      <email>amber.sowles@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Torri Metz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset will be shared per NIH policy after the completion and publication of the main analyses.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

